BR9908278A - Uso de agentes de melhoria de penetração e de rompimento de barreiras da pele, melhorar a resposta transcutânea imune induzida pela etoxina de ribosilatação de adp - Google Patents
Uso de agentes de melhoria de penetração e de rompimento de barreiras da pele, melhorar a resposta transcutânea imune induzida pela etoxina de ribosilatação de adpInfo
- Publication number
- BR9908278A BR9908278A BR9908278-0A BR9908278A BR9908278A BR 9908278 A BR9908278 A BR 9908278A BR 9908278 A BR9908278 A BR 9908278A BR 9908278 A BR9908278 A BR 9908278A
- Authority
- BR
- Brazil
- Prior art keywords
- improve
- transcutaneous
- immune
- agents
- penetration
- Prior art date
Links
- 230000035515 penetration Effects 0.000 title abstract 3
- 230000004044 response Effects 0.000 title abstract 2
- 230000005730 ADP ribosylation Effects 0.000 title 1
- 230000008591 skin barrier function Effects 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 abstract 1
- 230000005875 antibody response Effects 0.000 abstract 1
- 239000013043 chemical agent Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000002095 exotoxin Substances 0.000 abstract 1
- 231100000776 exotoxin Toxicity 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7585098P | 1998-02-25 | 1998-02-25 | |
| US7585698P | 1998-02-25 | 1998-02-25 | |
| PCT/US1999/004128 WO1999043350A1 (en) | 1998-02-25 | 1999-02-25 | Use of skin penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response induced by adp-ribosylating exotoxin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9908278A true BR9908278A (pt) | 2002-01-02 |
Family
ID=26757358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9908278-0A BR9908278A (pt) | 1998-02-25 | 1999-02-25 | Uso de agentes de melhoria de penetração e de rompimento de barreiras da pele, melhorar a resposta transcutânea imune induzida pela etoxina de ribosilatação de adp |
Country Status (9)
| Country | Link |
|---|---|
| EP (2) | EP2286834A3 (enExample) |
| JP (2) | JP4875799B2 (enExample) |
| AT (2) | ATE365050T1 (enExample) |
| AU (1) | AU3311599A (enExample) |
| BR (1) | BR9908278A (enExample) |
| CA (1) | CA2321596C (enExample) |
| DE (2) | DE69910743T2 (enExample) |
| ES (1) | ES2289200T3 (enExample) |
| WO (1) | WO1999043350A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US20060002949A1 (en) | 1996-11-14 | 2006-01-05 | Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. | Transcutaneous immunization without heterologous adjuvant |
| US6797276B1 (en) | 1996-11-14 | 2004-09-28 | The United States Of America As Represented By The Secretary Of The Army | Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response |
| US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| EP1486215A3 (en) * | 1997-03-21 | 2006-04-12 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
| JP4932086B2 (ja) * | 1999-04-08 | 2012-05-16 | インターセル ユーエスエイ、インコーポレイテッド | 経皮的免疫のための乾燥製剤 |
| US20030078499A1 (en) | 1999-08-12 | 2003-04-24 | Eppstein Jonathan A. | Microporation of tissue for delivery of bioactive agents |
| US6835184B1 (en) | 1999-09-24 | 2004-12-28 | Becton, Dickinson And Company | Method and device for abrading skin |
| US8465468B1 (en) | 2000-06-29 | 2013-06-18 | Becton, Dickinson And Company | Intradermal delivery of substances |
| US7030228B1 (en) | 1999-11-15 | 2006-04-18 | Miltenyi Biotec Gmbh | Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby |
| US6595947B1 (en) | 2000-05-22 | 2003-07-22 | Becton, Dickinson And Company | Topical delivery of vaccines |
| GB0017999D0 (en) | 2000-07-21 | 2000-09-13 | Smithkline Beecham Biolog | Novel device |
| ES2310201T3 (es) * | 2001-02-13 | 2009-01-01 | Government Of The United States Of America, As Represented By The Secretary Of The Army | Vacuna para inmunizacion transcutanea contra la diarrea de los viajeros. |
| AU2002252378B2 (en) | 2001-03-19 | 2007-10-18 | Intercell Usa, Inc. | Transcutaneous immunostimulation |
| CN1516595A (zh) * | 2001-03-19 | 2004-07-28 | Iomai公司 | 用于经皮免疫的贴剂 |
| EP1450855B1 (en) * | 2001-05-23 | 2009-08-26 | Duotol Ab | Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof |
| WO2002100476A2 (en) | 2001-06-08 | 2002-12-19 | Becton, Dickinson And Company | Device for manipulating a needle or abrader array |
| WO2003002069A2 (en) | 2001-06-29 | 2003-01-09 | Becton, Dickinson And Company | Intradermal delivery of vaccines and gene therapeutic agents via microcannula |
| CA2457804C (en) | 2001-08-13 | 2012-10-16 | University Of Rochester | Transcutaneous immunization against papillomavirus with papillomavirus virus-like particles |
| WO2003052117A2 (en) * | 2001-09-19 | 2003-06-26 | Massachusetts Institute Of Technology | Methods and products related to non-viral transfection |
| CA2929300C (en) | 2002-03-11 | 2019-04-16 | Nitto Denko Corporation | Transdermal drug delivery patch system, method of making same and method of using same |
| US9918665B2 (en) | 2002-03-11 | 2018-03-20 | Nitto Denko Corporation | Transdermal porator and patch system and method for using same |
| JP4764626B2 (ja) | 2002-05-06 | 2011-09-07 | ベクトン・ディキンソン・アンド・カンパニー | 薬剤の薬物動力学を制御する方法およびデバイス |
| US20040009180A1 (en) * | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
| CA2500911A1 (en) * | 2002-10-02 | 2004-04-15 | Nordic Vaccine Technology A/S | Composition for vaccination |
| WO2004065575A2 (en) | 2003-01-15 | 2004-08-05 | Research Institute For Genetic And Human Therapy (Right) | Dna compositon and uses thereof |
| US8016811B2 (en) | 2003-10-24 | 2011-09-13 | Altea Therapeutics Corporation | Method for transdermal delivery of permeant substances |
| EP1708744A4 (en) * | 2003-12-09 | 2009-07-15 | Intercell Usa Inc | GM1 Binding Dereficent Exotoxins for Use as Immunoinguarantees |
| AU2005251676B2 (en) | 2004-03-03 | 2011-09-29 | Revance Therapeutics, Inc. | Compositions and methods for topical diagnostic and therapeutic transport |
| US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
| US9180081B2 (en) | 2005-03-03 | 2015-11-10 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
| CN101912288A (zh) | 2005-09-02 | 2010-12-15 | 因特赛尔美国公司 | 经皮递送疫苗和透皮递送药物的装置及其应用 |
| JP5186678B2 (ja) * | 2005-10-13 | 2013-04-17 | 財団法人ヒューマンサイエンス振興財団 | 経皮抗原投与のための抗原キット |
| EP2357000A1 (en) | 2005-10-18 | 2011-08-17 | Novartis Vaccines and Diagnostics, Inc. | Mucosal and systemic immunizations with alphavirus replicon particles |
| FR2924349B1 (fr) | 2007-12-03 | 2010-01-01 | Dbv Tech | Methode de desensibilitation aux allergenes |
| WO2010013350A1 (ja) | 2008-08-01 | 2010-02-04 | Ａｓｐｉｏｎ株式会社 | Ｓ／ｏ型経皮免疫剤 |
| DE102011018499A1 (de) | 2011-04-23 | 2012-10-25 | Emc Microcollections Gmbh | Topische Nanopartikel-Vakzine zur Immunstimulation der dendritischen Zellen in der Haut |
| WO2014044690A1 (en) | 2012-09-18 | 2014-03-27 | Valneva Austria Gmbh | Improved vaccines |
| JP6577795B2 (ja) * | 2014-09-03 | 2019-09-18 | 日東電工株式会社 | ビスホスホネート剤を含む細胞性免疫用ワクチン医薬組成物 |
| KR20220147278A (ko) | 2021-04-27 | 2022-11-03 | (주)아모레퍼시픽 | 리포푸신 축적 억제 또는 리포푸신 제거용 조성물 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4810499A (en) * | 1984-10-01 | 1989-03-07 | Biotek, Inc. | Transdermal drug delivery system and method |
| JPS6468327A (en) * | 1987-09-08 | 1989-03-14 | Teisan Seiyaku Kk | Warming type insulin-containing plaster |
| GB9513371D0 (en) * | 1995-06-30 | 1995-09-06 | Biocine Spa | Immunogenic detoxified mutant toxins |
| JPH0679002A (ja) * | 1993-12-14 | 1994-03-22 | Hisamitsu Pharmaceut Co Inc | 経皮投与用パッチシステム |
| US5989586A (en) * | 1992-10-05 | 1999-11-23 | Cygnus, Inc. | Two-phase matrix for sustained release drug delivery device |
| US5679647A (en) * | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
| JPH07304690A (ja) * | 1994-05-13 | 1995-11-21 | Advanced Sukin Res Kenkyusho:Kk | 角質溶解剤、経皮吸収促進剤及び皮膚外用製剤 |
| JP2701005B2 (ja) * | 1994-09-07 | 1998-01-21 | 株式会社林原生物化学研究所 | 減感作剤 |
| JPH0912448A (ja) * | 1995-04-28 | 1997-01-14 | Read Chem Kk | 薬物放出制御型経皮吸収製剤 |
| WO1996037256A1 (en) * | 1995-05-22 | 1996-11-28 | Silicon Microdevices, Inc. | Micromechanical patch for enhancing the delivery of compounds through the skin |
| JPH09124468A (ja) * | 1995-10-27 | 1997-05-13 | Nippon Zoki Pharmaceut Co Ltd | 薬剤内包外皮用貼付剤 |
| CO4600681A1 (es) * | 1996-02-24 | 1998-05-08 | Boehringer Ingelheim Pharma | Composicion farmaceutica para la modulacion inmunitaria |
| JPH1025243A (ja) * | 1996-07-09 | 1998-01-27 | Showa Denko Kk | 鎮痛消炎外用貼付剤 |
| US5980898A (en) * | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
-
1999
- 1999-02-25 JP JP2000533145A patent/JP4875799B2/ja not_active Expired - Fee Related
- 1999-02-25 AU AU33115/99A patent/AU3311599A/en not_active Abandoned
- 1999-02-25 WO PCT/US1999/004128 patent/WO1999043350A1/en not_active Ceased
- 1999-02-25 BR BR9908278-0A patent/BR9908278A/pt not_active Application Discontinuation
- 1999-02-25 ES ES03007948T patent/ES2289200T3/es not_active Expired - Lifetime
- 1999-02-25 DE DE69910743T patent/DE69910743T2/de not_active Expired - Lifetime
- 1999-02-25 AT AT03007948T patent/ATE365050T1/de active
- 1999-02-25 AT AT99936034T patent/ATE247979T1/de not_active IP Right Cessation
- 1999-02-25 EP EP10012335A patent/EP2286834A3/en not_active Withdrawn
- 1999-02-25 EP EP99936034A patent/EP1061951B1/en not_active Expired - Lifetime
- 1999-02-25 DE DE69936355T patent/DE69936355T2/de not_active Expired - Lifetime
- 1999-02-25 CA CA2321596A patent/CA2321596C/en not_active Expired - Fee Related
-
2011
- 2011-10-13 JP JP2011225680A patent/JP2012041355A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999043350A1 (en) | 1999-09-02 |
| EP2286834A2 (en) | 2011-02-23 |
| JP2012041355A (ja) | 2012-03-01 |
| JP4875799B2 (ja) | 2012-02-15 |
| DE69936355T2 (de) | 2008-02-21 |
| ES2289200T3 (es) | 2008-02-01 |
| JP2002504522A (ja) | 2002-02-12 |
| DE69910743T2 (de) | 2004-07-08 |
| CA2321596A1 (en) | 1999-09-02 |
| AU3311599A (en) | 1999-09-15 |
| CA2321596C (en) | 2012-05-29 |
| DE69910743D1 (de) | 2003-10-02 |
| EP2286834A3 (en) | 2012-01-25 |
| ATE247979T1 (de) | 2003-09-15 |
| DE69936355D1 (de) | 2007-08-02 |
| ATE365050T1 (de) | 2007-07-15 |
| EP1061951B1 (en) | 2003-08-27 |
| EP1061951A1 (en) | 2000-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9908278A (pt) | Uso de agentes de melhoria de penetração e de rompimento de barreiras da pele, melhorar a resposta transcutânea imune induzida pela etoxina de ribosilatação de adp | |
| Salim et al. | Scour around exposed pile foundations | |
| ES2115626T3 (es) | Anticuerpo monoclonal humano especifico al antigeno de superficie de la membrana de las celulas cancerosas. | |
| IT8722185A0 (it) | Codice di identificazione rilevabile magneticamente per contrassegnare prodotti, documenti e simili. | |
| BR9806747A (pt) | Sistema terapêutico transdérmico. | |
| BRPI0208301B8 (pt) | ácido nucléico isolado, e, composição | |
| ES2171236T3 (es) | Vidrio de sosa-cal-silice sustancialmente libre de niquel que presenta una baja transmitancia en los intervalos de energia u.v., visible e i.r. | |
| BRPI0408167A (pt) | conjugados de polissacarìdeo-proteìna veìculo adesina da superfìcie estafilocócica para imunização contra infecções nosocomiais | |
| BRPI0412567A (pt) | anticorpo humano isolado, método de tratamento de uma condição causada pela expressão aumentada de ngf ou pela sensibilidade aumentada ao ngf em um paciente, composição farmacêutica, método para detectar ngf em uma amostra biológica, molécula de ácido nucleico, célula hospedeira, linhagem celular isolada, agente de ligação especìfica em ngf, anticorpo humano isolado ou fragmento de imunoglobulina imunologicamente funcional ou um ligante de antìgeno do mesmo, polinucleotìdeo, vetor de expressão, medicamento para tratar um distúrbio doloroso ou uma condição associada com a expressão aumentada de ngf ou a sensibilidade aumentada ao ngf, e, uso de uma quantidade farmaceuticamente efetiva de anticorpo | |
| BR0206507A (pt) | Sistema para controle de patógenos | |
| BR0113112A (pt) | Anticorpos, de integrina antidual, composições, métodos e usos | |
| BR9814282A (pt) | "composições e métodos para tratamento de distúrbio de déficit de atenção e distúrbio de déficit/hiperatividade de atenção com metilfenidato" | |
| BR9906660A (pt) | Processo para medir vìrus da hepatite c | |
| BRPI0411611A (pt) | elementos de segurança e caracterìsticas de segurança com efeitos cromóforos | |
| Lee et al. | Mucosal immunization with a genetically engineered pertussis toxin S1 fragment-cholera toxin subunit B chimeric protein | |
| BRPI0408878A (pt) | sistema e método para controle de insetos | |
| EP0910396A4 (en) | ISOLATED NUCLEIC ACID MOLECULES ENCODING THE GAGE TUMOR REPELLENT REPELLENTANT, THE TUMOR REPELLENT REPELLENTANT AND ITS USE | |
| EP1354896A4 (en) | NEW MONOCLONAL ANTIBODY | |
| Nguyen et al. | Humoral responses to Porphyromonas gingivalis gingipain adhesin domains in subjects with chronic periodontitis | |
| Robbins et al. | A rebuttal: epidemic and endemic meningococcal meningitis in sub-Saharan Africa can be prevented now by routine immunization with group A meningococcal capsular polysaccharide vaccine | |
| EP1356823A3 (en) | Use of skin penetration enhancers and barrier disruption agents to enhance transcutaneous immune response induced by ADP-ribosylating exotoxin | |
| BR9404004A (pt) | Poliptídeo isolado fragmento antigênico parte derivado ou análogo molécula de ácido nucléico método para reduzir o alastramento de um parasita helmíntico e composição de vacina | |
| IT8920953V0 (it) | Chiusura di sicurezza in particolare per flaconi di medicinali o simili. | |
| BR0115728A (pt) | Análise da expressão de ácidos nucléicos kiaa e polipeptìdeos úteis no diagnóstico e tratamento de cáncer de próstata | |
| ES2080235T3 (es) | Elemento analitico en seco para analizar salicilatos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25G | Requested change of headquarter approved | ||
| B25A | Requested transfer of rights approved |
Free format text: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 11 E 25 DA LPI. |
|
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |